Sitacord is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. ​

Sitagliptin 50mg

Sitacord lowers blood sugar by increasing insulin release and decreasing glucagon levels through the inhibition of the DPP-4 enzyme.

Sitagliptin primarily works in the intestines.​

1. DPP-4 Inhibition: Sitacord blocks the DPP-4 enzyme. This enzyme is responsible for breaking down incretin hormones, which are naturally produced in the body in response to meals.​
2. Increased Insulin Release: When DPP-4 is inhibited by Sitacord, the incretin hormones stimulate the pancreas to release more insulin, helping to lower blood sugar levels after meals.​
3. Decreased Glucagon Release: In addition to increasing insulin, Sitacord also helps to reduce the release of glucagon, a hormone that raises blood sugar levels.

This dual action contributes to better blood sugar control